Overview
Lutetium Lu 177 vipivotide tetraxetan is included in DrugStatusIndex as part of a structured FDA-status reference covering medications, compounds, peptides, and drug-name search terms.
FDA Status Details
Current working status: FDA Approved. FDA-approved cancer-related medication or biologic; indications, combinations, and patient selection can vary by cancer type and labeling.
Availability & Prescription Context
Available through licensed pharmacies, specialty pharmacies, infusion centers, or hospital oncology channels when prescribed.
Compounded & Private Label Considerations
Commercial FDA-approved oncology products or approved generics may be available; compounding is generally not appropriate when approved products meet patient needs.